Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2015 September;67(3) > Minerva Urologica e Nefrologica 2015 September;67(3):187-96



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Per citare questo articolo



Minerva Urologica e Nefrologica 2015 September;67(3):187-96


lingua: Inglese

Association of calcium antagonist use with lower hemoglobin levels in hemodialysis patients

Cikrikcioglu M. A. 1, Ozdemir A. A. 2, Sekin Y. 1, Yalcin B. 2, Altay M. 2, Gundogdu A. 2, Erkal S. N. 3, Kazancioglu R. 1, Erkoc R. 1

1 Department of Internal Medicine, Bezmialem Vakif University Medical Faculty, Istanbul, Turkey; 2 Department of Internal Medicine, Division of Nephrology, Taksim Training and Research Hospital, Istanbul, Turkey; 3 Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey


AIM: Objective of the present study was to investigate whether calcium antagonist use is associated with lower hemoglobin levels and/or higher erythropoiesis stimulating agent (ESA) requirement in hemodialysis patients.
METHODS: A total of 130 adult hemodialysis patients were classified into two groups based on calcium antagonist usage for a period of at least 3 months as calcium antagonist users and calcium antagonist non-users. The two groups were compared cross-sectionally in a retrospective manner in terms of demographics, chronic kidney disease aetiologies, Charlson’s Comorbidty Index, blood pressure, type of dialysis access, interdialytic body weight gain, cardiothoracic index, complete blood count, biochemistry, regular medication use and consumption of ESA. All independent variables that were different between the groups were subjected to logistic regression analysis. Linear regression analysis with dependent variable of hemoglobin value was also performed
RESULTS: ESA consumption and blood pressure were higher, diabetic nephropathy, doxazosin and ACE inhibitor use were more frequent, and hemoglobin was lower in the calcium antagonist users. After logistic regression analysis, diabetic nephropathy, doxazosin use, ACE inhibitor use and lower hemoglobin were associated with calcium antagonist use. After lineer regression analysis, Age, BMI, gender, predialysis creatinine value, dialysis duration, systolic and diastolic blood pressure, doxazosin use, diabetes mellitus and diabetic nephropathy were not related with hemoglobin value. But, higher amount of ESA consumption, ACE inhibitor use and calcium antagonist use were significantly associated with lower hemoglobin value.
CONCLUSION: CA use was associated with lower hemoglobin levels in our hemodialysis patient population.

inizio pagina